SCHEMBL6714045

SCHEMBL6714045

COC(=O)c1ccc(NC(=O)N(S)C(C(=O)Nc2ccccc2C)c2ccccc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.61
RAB9A P51151 4/20 0.61
NPC1 O15118 3/20 0.61
ALDH1A1 P00352 4/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
GAA P10253 1/20 0.52
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.46
HTT P42858 2/20 0.46
KDM4E B2RXH2 1/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
POLB P06746 1/20 0.44
ROCK2 O75116 1/20 0.44
PTPN1 P18031 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6718945 0.90 ALDH1A1 (0.61) MAPTRAB9ANPC1ALDH1A1L3MBTL1
SCHEMBL6715452 0.89 ALDH1A1 (0.57) MAPTRAB9ANPC1ALDH1A1L3MBTL1
SCHEMBL6719554 0.88 NPY5R (0.50) MAPTRAB9ANPC1ALDH1A1GAA
SCHEMBL6718048 0.85 KLK7 (0.46) MAPTRAB9ANPC1ALDH1A1KMT2A
SCHEMBL6714251 0.85 MAPT (0.61) MAPTRAB9ANPC1ALDH1A1L3MBTL1
SCHEMBL6716819 0.85 MAPT (0.61) MAPTRAB9ANPC1ALDH1A1L3MBTL1
SCHEMBL6723214 0.84 ALDH1A1 (0.52) MAPTRAB9ANPC1ALDH1A1L3MBTL1
SCHEMBL6717231 0.83 MAPT (0.57) MAPTRAB9ANPC1ALDH1A1L3MBTL1
SCHEMBL6713916 0.83 MAPT (0.59) MAPTRAB9ANPC1ALDH1A1L3MBTL1
SCHEMBL6715874 0.82 NPC1 (0.58) MAPTRAB9ANPC1ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 MAPT 427/4885RAB9A 2094/4885NPC1 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.